ArticleiScience2026
East Asia and high-income Asia Pacific burden of diabetes mellitus from 1990 to 2023.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) remains a major health challenge in East Asia and the high-income Asia Pacific, yet systematic subtype-specific comparisons are lacking. Using Global Burden of Disease Study 2023 data, we analyzed age-standardized incidence, prevalence, mortality, and disability-adjusted life year (DALY) rates for DM subtypes from 1990 to 2023, calculated mortality-to-incidence ratios (MIRs) and population-attributable fractions, and projected outcomes to 2050. In 2023, East Asia had higher MIR (0.04) and mortality (8.26/100,000) than the high-income Asia Pacific (0.02 and 4.50/100,000), with type 2 diabetes (T2DM) comprising >94% of cases. High body-mass index was the primary T2DM risk factor (49.3%); T1DM burden was linked to temperature exposure. Under the reference scenario, T2DM mortality and DALY rates will rise by 2050, but optimized behavioral and metabolic interventions could reduce DM DALY rates by >84% in East Asia and >70% in the high-income Asia Pacific, highlighting the urgent need for targeted, risk-factor-specific diabetes control strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.